tirzepatide court case today Minus one of its GLP-1 cash cows, compounding group sues FDA Compounding pharmacies can resume making

This dual approval underscores its powerful effects on both blood sugar control and weight

There were no clinically meaningful differences in tirzepatide exposure between the abdomen, thigh, or upper arm

Zepbound (tirzepatide): As a weekly injection, Zepbound offers the highest weight loss, targeting GLP-1 and GIP receptors, with up to 20.9% body weight reduction

Both Zepbound and Mounjaro work by mimicking the effects of the GLP-1 hormone

In adult patients with type 2 diabetes mellitus, treatment with MOUNJARO produced a statistically significant reduction from baseline in HbA1c compared to placebo

By day 25, trace amounts persist but functional activity is minimal